[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370674-105":59,"doc-detail-370674-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","global-transcriptional-complexity-of-estrogen-receptor-low-positive-breast-cancers-in-the-prospective-swedish-population-based-scan-b-cohort-research-findings","Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort - Research Findings","","Estrogen receptor (ER)–low tumors, defined by 1% to 10% nuclear IHC staining, may represent a distinct breast-cancer entity, yet their molecular biology and optimal clinical management remain uncertain. This study analyzed primary tumors from the Sweden Cancerome Analysis Network-Breast (SCAN-B) cohort, comparing ER-low with ER-negative and ER-positive groups. Results show strong transcriptomic overlap with ER-negative tumors, downregulated ER signaling, and failure of unsupervised clustering to separate ER-low from TNBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/global-transcriptional-complexity-of-estrogen-receptor-low-positive-breast-cancers-in-the-prospective-swedish-population-based-scan-b-cohort-research-findings/370674/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/global-transcriptional-complexity-of-estrogen-receptor-low-positive-breast-cancers-in-the-prospective-swedish-population-based-scan-b-cohort-research-findings/370674.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical uncertainty motivates this study on ER-low breast cancers?","Question",{"text":112,"@type":113},"Whether ER-low tumors (1%–10% ER by IHC) are a distinct molecular entity and how that affects clinical management and development of new therapies remains unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ER-low tumors defined and analyzed in the SCAN-B cohort?",{"text":117,"@type":113},"Primary breast tumors from the Sweden Cancerome Analysis Network-Breast (SCAN-B) cohort were assessed, with ER-low classified as tumors showing 2% of cases and compared using transcriptional patterns, inflammatory infiltration, and prognosis against ER-negative and ER-positive groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the findings suggest about the molecular identity of ER-low/HER2-negative tumors?",{"text":121,"@type":113},"ER-low/HER2-negative tumors largely overlap transcriptionally with ER-negative disease, are predominantly nonluminal, and are not a distinct molecular entity but instead an integral part of TNBC; however, borderline ER-low cases may show endocrine responsiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370674,1790360118,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Global Transcriptional Complexity of Estrogen Receptor–Low Positive Breast Cancers in the Prospective Swedish Population–Based SCAN-B Cohort  \nSiker Kimbung1,2, Srinivas Veerla1,2, Kadum Muhammad2,3, Anna Ehinger1,2,4, Johan Vallon-Christersson1,2, Martin Malmberg2,3, and Niklas Loman1,2,3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: There is uncertainty whether estrogen receptor (ER)– low tumors with 1% to 10% IHC staining of nuclei represent a distinct molecular biological entity of breast cancer, posing significant challenges for their clinical management and the development of novel therapies. We aimed to elucidate ER-low tumor biology. Experimental Design: We analyzed primary breast tumors included in the Swedish population–based Sweden Cancerome Analysis Network-Breast (SCAN-B) cohort, 2%(n ¼ 174) of which were classified as ER-low. Transcriptional patterns, tumor inflammatory infiltration, and prognosis were compared between ER-low versus ER-negative (ER-neg; 0%) and ER-positive (ER-pos; >10%) tumors. Results: The transcriptomes of ER-low and ER-neg tumors remarkably overlapped, displaying predominantly nonluminal PAM50 subtypes and downregulated ER signaling. All triplenegative breast cancer (TNBC) molecular subtypes were represented within ER-low/HER2-negative breast cancer. Unsupervised clustering algorithms failed to segregate ER-low/HER2-negative from TNBC tumors, and only two genes showed significant\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | differential expression above a 1.5-fold difference between the groups. However, borderline ER-low tumors (with exactly 10% ER) were mostly assigned labels associated with luminal disease biology, suggesting possible endocrine responsiveness. Lymphocyte infiltration was comparable between ER-low and ER-neg but was significantly higher relative to ER-pos tumors. Within ER-low/HER2-negative disease, hormone receptor positivity and low/intermediate PAM50 risk of recurrence score inferred from RNA sequencing data and lymphocyte fraction ≥30% were respectively associated with a better prognosis.\u003Cbr>Conclusions: ER-low/HER2-negative is not a distinct breast cancer molecular biological entity but an integral part of TNBC, deserving similar treatments. Nonetheless, a few borderline cases with moderately active ER signaling can potentially respond to endocrine therapies. Hormone receptor–related signatures and tumorinfiltrating lymphocytes may stratify ER-low/HER2-negative tumors according to the risk of recurrence. The true benefit of endocrine therapies in ER-low breast cancer requires prospective investigation. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nThe estrogen receptor (ER) is expressed by more than 75% of breast cancers and is currently the most consequential biomarker for determining prognosis and for therapeutic decision-making in the clinical management of early and advanced breas","cbCaijrnomD8bAwd","https://ap.wps.com/l/cbCaijrnomD8bAwd","pdf",5982221,15,"English","# Introduction\n# Purpose\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"What clinical uncertainty motivates this study on ER-low breast cancers?\",\"answer\":\"Whether ER-low tumors (1%–10% ER by IHC) are a distinct molecular entity and how that affects clinical management and development of new therapies remains unclear.\"},{\"question\":\"How were ER-low tumors defined and analyzed in the SCAN-B cohort?\",\"answer\":\"Primary breast tumors from the Sweden Cancerome Analysis Network-Breast (SCAN-B) cohort were assessed, with ER-low classified as tumors showing 2% of cases and compared using transcriptional patterns, inflammatory infiltration, and prognosis against ER-negative and ER-positive groups.\"},{\"question\":\"What do the findings suggest about the molecular identity of ER-low/HER2-negative tumors?\",\"answer\":\"ER-low/HER2-negative tumors largely overlap transcriptionally with ER-negative disease, are predominantly nonluminal, and are not a distinct molecular entity but instead an integral part of TNBC; however, borderline ER-low cases may show endocrine responsiveness.\"}]","Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort - Research Findings | PDF",1790189719,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bbfcaa97160e6ba81d51fa74a2e1691.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6288dffb41ff32bc8f482ede3cca7638.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f2673c30136e9fbf34362c5e7e0c6e7.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e93c29026fca890358482b22b12882e3.webp",980,1311]